Stockpolly
Search

Categories·Biotech

New Drug Development

Companies that use cell culture and genetic recombination to develop groundbreaking new drugs and export the underlying technology.

−1.91% today·589 stocks·3 sub-categories

Stocks

By market cap · 589 stocks

  1. 1AbbVieABBVImmunology drugmaker behind Skyrizi, Rinvoq, and Botox$451.38B−1.04%
  2. 2MerckMRKMaker of Keytruda, vaccines, and animal medicines$366.18B−0.82%
  3. 3AstraZeneca (ADR)AZNOncology-led developer of specialty medicines$252.33B−1.12%
  4. 4AmgenAMGNMaker of Prolia, Repatha, and rare-disease medicines$233.38B−1.05%
  5. 5Gilead SciencesGILDDeveloper of HIV, liver-disease, and cancer medicines$180.87B−2.16%
  6. 6Bristol-Myers SquibbBMYDeveloper of Eliquis, Opdivo and specialty medicines$136.00B−0.57%
  7. 7RegeneronREGNMaker of Dupixent, EYLEA HD, and Libtayo$81.82B−1.69%
  8. 8argenx (ADR)ARGXDeveloper of VYVGART autoimmune medicines$63.63B−3.35%
  9. 9ModernaMRNADeveloper of mRNA vaccines and therapeutics$54.75B−3.35%
  10. 10Revolution MedicinesRVMDDeveloper of RAS(ON) oncology candidates$44.19B−5.91%
  11. 11BeOne Medicines (ADR)ONCDeveloper of BRUKINSA and TEVIMBRA oncology medicines$39.19B−1.54%
  12. 12BiogenBIIBNeuroscience medicines across MS and rare disease$32.28B−1.36%
  13. 13Alnylam PharmaceuticalsALNYRNAi medicines built around gene-silencing delivery$31.73B+0.23%
  14. 14Royalty PharmaRPRXBuyer and funder of drug royalties$26.97B−1.73%
  15. 15InsmedINSMTwo marketed pulmonary medicines and gene therapies$25.69B−2.38%
  16. 16BioNTech (ADR)BNTXComirnaty developer with an oncology pipeline$25.64B−8.36%
  17. 17IncyteINCYJakafi-led hematology, oncology, and immunology drug developer$25.21B−2.61%
  18. 18Roivant SciencesROIVVant-based developer of immunology medicines$25.07B−7.69%
  19. 19United TherapeuticsUTHRMaker of Tyvaso and investigational organ alternatives$21.88B−2.39%
  20. 20Genmab (ADR)GMABBuilder of antibody medicines and bispecific platforms$20.40B−2.58%
  21. 21Neurocrine BiosciencesNBIXDeveloper of INGREZZA and rare-disease medicines$15.49B−1.19%
  22. 22Jazz PharmaceuticalsJAZZSleep, epilepsy and oncology rare-disease medicines$15.36B−2.64%
  23. 23BridgeBio PharmaBBIOAttruby-led genetic disease drug developer$15.00B−2.67%
  24. 24ExelixisEXELBuilder of the cabozantinib oncology franchise$13.69B−1.52%
  25. 25Baxter InternationalBAXHospital infusion, connected-care, and injectable products$13.51B+0.77%
  26. 26BioMarinBMRNRare-disease therapies spanning enzymes and skeletal conditions$12.50B−0.98%
  27. 27Halozyme TherapeuticsHALOENHANZE platform for subcutaneous drug delivery$12.50B−1.47%
  28. 28Madrigal PharmaceuticalsMDGLMASH drug developer behind Rezdiffra$12.33B−1.81%
  29. 29Arrowhead PharmaceuticalsARWRDeveloper of targeted RNAi medicines$11.96B−4.15%
  30. 30Summit TherapeuticsSMMTDeveloper of ivonescimab for solid tumors$10.95B−4.33%
  31. 31Krystal BiotechKRYSTopical VYJUVEK and redosable genetic medicine pipeline$10.36B−1.73%
  32. 32Axsome TherapeuticsAXSMCNS medicines for depression, agitation, sleepiness, and migraine$10.24B−3.49%
  33. 33Ionis PharmaceuticalsIONSAntisense medicines with owned and partnered launches$10.15B−2.23%
  34. 34Kymera TherapeuticsKYMROral protein degraders for immunological diseases$9.72B−1.79%
  35. 35Praxis Precision MedicinesPRAXPrecision neuroscience drug developer for tremor and epilepsy$9.61B−6.18%
  36. 36Protagonist TherapeuticsPTGXPeptide-drug developer behind ICOTYDE and rusfertide$9.28B−3.50%
  37. 37Crinetics PharmaceuticalsCRNXDeveloper of PALSONIFY and endocrine-disease therapies$8.99B+0.01%
  38. 38CytokineticsCYTKDeveloper of MYQORZO and cardiac muscle medicines$8.97B−7.43%
  39. 39VaxcytePCVXDeveloper of high-valency pneumococcal vaccines$8.64B−2.20%
  40. 40ImmunovantIMVTDeveloper of imeroprubart for autoimmune diseases$8.50B−6.00%
  41. 41ImmunityBioIBRXMaker of ANKTIVA and cellular immunotherapies$8.43B−4.17%
  42. 42Apogee TherapeuticsAPGELong-acting antibodies for inflammatory diseases$8.35B+0.00%
  43. 43Abivax (ADR)ABVXDeveloper of oral obefazimod for inflammation$8.32B−0.86%
  44. 44TG TherapeuticsTGTXCommercializer of BRIUMVI for relapsing multiple sclerosis$8.26B−3.25%
  45. 45Spyre TherapeuticsSYREDeveloper of long-acting immunology antibody combinations$7.85B−3.48%
  46. 46Rhythm PharmaceuticalsRYTMMC4R therapies for rare neuroendocrine obesity$7.35B−4.67%
  47. 47Scholar RockSRRKDeveloper of myostatin antibodies for neuromuscular diseases$6.93B−2.46%
  48. 48CG OncologyCGONCretostimogene developer and contract manufacturer$6.56B−5.92%
  49. 49Grifols (ADR)GRFSIntegrated plasma therapies and diagnostics$6.51B−1.66%
  50. 50ErascaERASDeveloper of pan-RAS and pan-KRAS cancer drugs$6.26B−7.47%